AxoGen (AXGN)
(Delayed Data from NSDQ)
$7.64 USD
-0.19 (-2.43%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $7.64 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Brokerage Reports
AxoGen, Inc. [AXGN]
Reports for Purchase
Showing records 21 - 40 ( 71 total )
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
2Q17 Earnings Preview: Positive Underlying Dynamics
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Upbeat Management Meeting; Raising PT to $17; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Faster Adoption Drives 1Q Upside; Raising PT to $14
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
No Gap in Opportunities - Travels w/ Management Reaffirm Bullish Outlook
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
1Q17 Preview: Outperforming in MedTech Year-to-Date Reflects Stable Fundamentals That Should Continue Throughout 2017
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
We are initiating coverage with a Buy rating and target price of $14.50.
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Positive Momentum to Continue in 2017; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Preannounces Positive 4Q16 Revenues and Maintains Favorable 2017 Growth Outlook; Reiterate
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Termination of Coverage -Analyst(s) Departure
Provider: DAWSON JAMES SECURITIES, INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
AxoGen''s Analyst Meeting Provides Us With Greater Confidence Of Its Robust, Long-Term Growth Prospects; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
3Q16 Results - In-line with Pre-announced Results; Raising PT to $12; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Highlights from JNJ''s 3Q16 Results Bode Well for the MedTech Sector; Most Positive Read
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
3Q16 Preview: Stable Growth Trends Through The End of 2016
Provider: WEDBUSH SECURITIES INC.
Company: AxoGen, Inc.
Industry: Medical - Generic Drugs
Announces Public Offering and Preannounces 3Q16 Revenues In Line With Consensus Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.